The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations

Katarzyna Kolasa, Z. Kaló, Vladimir Zah

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Introduction: According to some experts, there is still room for improvement with regard to the inclusion of ethical considerations in Health Technology Assessment (HTA). Areas covered: The pros and cons of the introduction of non-economic criteria in the HTA process in Central and Eastern Europe (CEE) are discussed. In comparison to Western Europe, financial considerations are even more important in CEE settings; however, it could also be said that attachment to equity and justice is part of CEE’s heritage. Therefore, the trade-off between conflicting principles is evaluated. Expert commentary: To ensure the right balance between equity and efficiency in decision making, the current HTA framework has to be further augmented to allow all conflicting criteria to be addressed to a satisfactory degree. Following other examples, the applicability of multi criteria decision analysis technique to CEE settings should be further investigated.

Original languageEnglish
Pages (from-to)483-488
Number of pages6
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume16
Issue number4
DOIs
Publication statusPublished - Jul 3 2016

Fingerprint

Eastern Europe
Biomedical Technology Assessment
Costs and Cost Analysis
Decision Support Techniques
Social Justice
Decision Making

Keywords

  • Central and Eastern Europe (CEE)
  • cost effectiveness threshold
  • equity and justice
  • equity- efficiency trade-off
  • Health technology assessment
  • non-economic pricing and reimbursement criteria
  • pricing and reimbursement

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Cite this

The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe : issues, trends and recommendations. / Kolasa, Katarzyna; Kaló, Z.; Zah, Vladimir.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 16, No. 4, 03.07.2016, p. 483-488.

Research output: Contribution to journalReview article

@article{b95c65485a5d4372b8ee0de9e5ddaf17,
title = "The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations",
abstract = "Introduction: According to some experts, there is still room for improvement with regard to the inclusion of ethical considerations in Health Technology Assessment (HTA). Areas covered: The pros and cons of the introduction of non-economic criteria in the HTA process in Central and Eastern Europe (CEE) are discussed. In comparison to Western Europe, financial considerations are even more important in CEE settings; however, it could also be said that attachment to equity and justice is part of CEE’s heritage. Therefore, the trade-off between conflicting principles is evaluated. Expert commentary: To ensure the right balance between equity and efficiency in decision making, the current HTA framework has to be further augmented to allow all conflicting criteria to be addressed to a satisfactory degree. Following other examples, the applicability of multi criteria decision analysis technique to CEE settings should be further investigated.",
keywords = "Central and Eastern Europe (CEE), cost effectiveness threshold, equity and justice, equity- efficiency trade-off, Health technology assessment, non-economic pricing and reimbursement criteria, pricing and reimbursement",
author = "Katarzyna Kolasa and Z. Kal{\'o} and Vladimir Zah",
year = "2016",
month = "7",
day = "3",
doi = "10.1080/14737167.2016.1215917",
language = "English",
volume = "16",
pages = "483--488",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe

T2 - issues, trends and recommendations

AU - Kolasa, Katarzyna

AU - Kaló, Z.

AU - Zah, Vladimir

PY - 2016/7/3

Y1 - 2016/7/3

N2 - Introduction: According to some experts, there is still room for improvement with regard to the inclusion of ethical considerations in Health Technology Assessment (HTA). Areas covered: The pros and cons of the introduction of non-economic criteria in the HTA process in Central and Eastern Europe (CEE) are discussed. In comparison to Western Europe, financial considerations are even more important in CEE settings; however, it could also be said that attachment to equity and justice is part of CEE’s heritage. Therefore, the trade-off between conflicting principles is evaluated. Expert commentary: To ensure the right balance between equity and efficiency in decision making, the current HTA framework has to be further augmented to allow all conflicting criteria to be addressed to a satisfactory degree. Following other examples, the applicability of multi criteria decision analysis technique to CEE settings should be further investigated.

AB - Introduction: According to some experts, there is still room for improvement with regard to the inclusion of ethical considerations in Health Technology Assessment (HTA). Areas covered: The pros and cons of the introduction of non-economic criteria in the HTA process in Central and Eastern Europe (CEE) are discussed. In comparison to Western Europe, financial considerations are even more important in CEE settings; however, it could also be said that attachment to equity and justice is part of CEE’s heritage. Therefore, the trade-off between conflicting principles is evaluated. Expert commentary: To ensure the right balance between equity and efficiency in decision making, the current HTA framework has to be further augmented to allow all conflicting criteria to be addressed to a satisfactory degree. Following other examples, the applicability of multi criteria decision analysis technique to CEE settings should be further investigated.

KW - Central and Eastern Europe (CEE)

KW - cost effectiveness threshold

KW - equity and justice

KW - equity- efficiency trade-off

KW - Health technology assessment

KW - non-economic pricing and reimbursement criteria

KW - pricing and reimbursement

UR - http://www.scopus.com/inward/record.url?scp=84982217640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982217640&partnerID=8YFLogxK

U2 - 10.1080/14737167.2016.1215917

DO - 10.1080/14737167.2016.1215917

M3 - Review article

C2 - 27467881

AN - SCOPUS:84982217640

VL - 16

SP - 483

EP - 488

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 4

ER -